Mordor Intelligence, LLP. Contributes to the Diabetes Awareness Month by Granting Free Access to Their Real-Time Exhaustive Research on Diabetes Care Drugs

Mordor Intelligence, LLP. Contributes to the Diabetes Awareness Month by Granting Free Access to Their Real-Time Exhaustive Research on Diabetes Care Drugs

PR Newswire

HYDERABAD, India, November 13, 2018

HYDERABAD, India, November 13, 2018 /PRNewswire/ --

On the occasion of World Diabetes Day, Mordor Intelligence reiterated its commitment to helping enterprises in the business of Diabetes Care Drugs by enabling them to make smart strategic decisions. The company has announced that it is offering a full access to its Intelligence Center on the Diabetes Care Drugs for FREE. With the successful launch of this Intelligence Center last month, Mordor is already ensuring that the benefits of this data reaches all possible enterprises in this space.

     (Logo: )

The data put together by Mordor Intelligence greatly strengthens the medical community's continuous research on understanding Diabetes and the drugs used in its treatment. This market intelligence data greatly benefits enterprises in making the right decisions, by helping foster a clear understanding of the various industry trends. The company is allowing enterprises FULL ACCESS to this exhaustive and precise data related to diabetes. This limited time Free access can be set up here:

Mordor's Intelligence Center on the Diabetes Care Drugs Market offers extensive and precise data spanning 15 segments under 4 categories, covering 25 countries from 5 regions. This data is additionally backed by the brand share information of 33 brands with an R&D pipeline. A key differentiator of this platform in comparison to similar services is the accuracy and timeliness of the data. This Intelligence Center is updated every quarter with significant changes reflecting real-time information. In addition, the platform is extremely user friendly and offers a seamless, intuitive  experience. In addition to Intelligence on Diabetes Care Drugs, Mordor also offers a comprehensive Intelligence Center on Diabetes Care Devices.

The coverage offered is as listed:


  1. Insulin
    1. Basal Insulin
    2. Bolus Insulin
    3. Human Insulin
    4. Human Insulin Inhaled
  2. Non-Insulin Injectables
    1. Amylin Analogue
    2. GLP-1 Agonist
  3. Oral Antidiabetic Drugs
    1. Alpha Glucosidase Inhibitors
    2. Biguanides
    3. Dopamine - B2 receptor agonist
    4. DPP-4 Inhibitors
    5. Meglitinide
    6. SGLT-2 Inhibitors
    7. Sulfonylureas
  4. Combination Drugs
    1. Insulin Combination
    2. Oral Combination


  1. Asia Pacific
    1. Australia
    2. China
    3. India
    4. Indonesia
    5. Japan
    6. Malaysia
    7. Philippines
    8. South Korea
    9. Thailand
    10. Vietnam
  2. Europe
    1. France
    2. Germany
    3. Italy
    4. Russia
    5. Spain
    6. United Kingdom
  3. Latin America
    1. Brazil
    2. Mexico
  4. North America
    1. Canada
    2. United States
  5. Middle East
    1. Egypt
    2. Iran
    3. Oman
    4. Saudi Arabia
    5. South Africa


  1. Afrezza
  2. Apidra
  3. Basaglar
  4. Bydureon
  5. Byetta
  6. Cycloset
  7. Farxiga/Forxiga
  8. Galvus
  9. Generic
  10. Humalog
  11. Humulin
  12. Insuman
  13. Invokana
  14. Janumet
  15. Januvia
  16. Jardiance
  17. Lantus
  18. Levemir
  19. Lyxumia
  20. Novolin/Human Insulin
  21. Novolog/NovoRapid
  22. NovoMix
  23. Onglyza
  24. Ryzodeg
  25. Suglat
  26. Symlin
  27. Toujeo
  28. Tradjenta
  29. Tresiba
  30. Trulicity
  31. Victoza
  32. Vipidia/Nesina
  33. Xultophy

Mordor Intelligence, LLP. operates in the business of industry analysis & consulting, helping clients shape their strategic decisions. Founded in 2013, and fully revenue-funded, Mordor is based out of Hyderabad, India. The company offers custom market intelligence and advisory services along with syndicated reports to help customers gain edge over competition. Mordor caters to over 500 clients across the globe in various industries.


Name: Sameeksha Bansal


Phone: +1-617-765-2493

Voltar noticias em Inglês